SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is experiencing heightened volatility as market participants react to recent geopolitical rhetoric from former President Trump, particularly concerning potential tariffs and comments about Greenland, which has sparked significant uncertainty among international allies. Community sentiment reflects apprehension about these developments, fueling discussions around a potential "Sell America" trade and a noticeable shift toward safe-haven assets like gold and silver amid broader economic and geopolitical concerns.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. is trending amid its announced record date for a new digital token initiative, which the community is discussing as a potential catalyst for a short squeeze. This development, coupled with ongoing geopolitical narratives and commentary surrounding its figurehead, fuels significant market speculation and contributes to its high volatility.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is highly active amidst intense discussions fueled by geopolitical developments, specifically related to rhetoric from Davos concerning Greenland and potential tariffs impacting European allies. Community sentiment is bifurcated, with many anticipating continued declines from global instability and upcoming interest rate decisions, while a significant portion of traders are actively buying the dip, expecting a customary market rebound despite the contentious headlines.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following a key licensing agreement with Pfizer for its Matrix-M adjuvant technology, which the community views as a significant validation for the platform and a catalyst for potential future collaborations. Many are actively discussing the stock's high short interest, anticipating a substantial market move as the short thesis weakens. Despite this positive development, debates continue around management's overall strategy to maximize shareholder value and secure additional deals for its pipeline assets.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending dramatically after announcing promising Phase 1 clinical trial results for its oral drug, soquelitinib, treating moderate to severe atopic dermatitis with strong efficacy and a favorable safety profile. The market is actively discussing the drug's potential, especially for patients resistant to current therapies, driving speculation of significant upside and a short squeeze, though some caution against the early trial stage and potential dilution.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a focal point of market discussion after recently upgrading its bid for Warner Bros. Discovery assets to an all-cash offer, a strategic move generating debate about its long-term growth prospects ahead of the upcoming earnings report. Community sentiment is sharply divided, with many seeing the stock as oversold and ripe for a rebound, while others express caution regarding the deal's implications and broader market headwinds.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple (AAPL) is currently experiencing highly polarized community sentiment, with many expressing frustration over its recent price decline, perceived lack of AI innovation, and broader market weakness. However, a strong counter-narrative highlights the stock as deeply oversold with historically low RSI levels, presenting a significant "buy the dip" opportunity ahead of its anticipated strong holiday quarter earnings. Geopolitical tensions and ongoing tariff discussions are further fueling volatility and shaping investor outlook on the tech giant.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following positive regulatory developments, as the FDA requested no new trials for its ANKTIVA cancer therapy's sBLA resubmission, signaling an accelerated path to market. The community is buzzing with optimism, anticipating substantial long-term growth driven by this key de-risking event and international market opportunities, while also discussing the potential for a significant short squeeze.

ProShares Trust - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

UVXY is trending amid intensified geopolitical rhetoric and upcoming central bank decisions, driving speculation for a potential surge in market volatility. While some traders anticipate significant upward movement, the community largely discusses its inherent decay, making it a popular instrument for short-selling and a challenging long-term hold. This highlights the ongoing tug-of-war between event-driven fear and the structural nature of volatility products.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The SPDR Dow Jones Industrial Average ETF (DIA) is trending due to escalating geopolitical tensions, particularly surrounding renewed tariff threats from former President Trump towards European allies over Greenland. Community discussions highlight widespread concerns about a potential market downturn, trade wars, and broader global instability, with many anticipating a significant market correction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 4.5% - Time to Sell?

Aligos Therapeutics (NASDAQ:ALGS) Trading Down 4.5% - Here's What Happened...

Does Aligos Therapeutics (ALGS) Have the Potential to Rally 737.74% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 737.7% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia

SNY wins FDA approval for Wayrilz, the first BTK inhibitor for immune thrombocytopenia, with broader rare disease studies underway.

RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study

Rocket Pharmaceuticals' shares soar as the FDA lifts its clinical hold on the pivotal Danon disease gene therapy study.

Wall Street Analysts Predict a 983.24% Upside in Aligos Therapeutics (ALGS): Here's  What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 983.2% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus

ALLO posts a narrower second-quarter 2025 loss. The company advances multiple CAR T programs targeting cancer and autoimmune diseases.

Aligos Therapeutics, Inc. (ALGS) Reports Q2 Loss, Misses Revenue Estimates

Aligos Therapeutics (ALGS) delivered earnings and revenue surprises of +34.89% and -3.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 5, 2018 and is headquartered in South San Francisco, CA.

Current Price	$7.93
Prev Close	$7.94
Open	$7.69
Dividend Yield	0.00%
50-Day Moving Average	$9.26
Beta	1.71
Avg. Volume	70,943.05
PE Ratio	-0.40

52-Week High	$34.37
52-Week Low	$3.76
Market Capitalization	$48.86M
EPS (Annual)	-$20.94
Price to Book	0.68
Revenue Per Employee	$56,357.14
Enterprise Value/EBITDA	N/A

ALGS
Aligos Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALGS News

ALGSAligos Therapeutics Inc